Fideuram Intesa Sanpaolo Private Banking S.P.A. Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

Fideuram Intesa Sanpaolo Private Banking S.P.A. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 35.0% during the 1st quarter, Holdings Channel.com reports. The fund owned 14,975 shares of the biopharmaceutical company’s stock after selling 8,072 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Regeneron Pharmaceuticals were worth $11,570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its stake in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after purchasing an additional 74,350 shares during the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,702,000. Mackenzie Financial Corp boosted its position in Regeneron Pharmaceuticals by 26.8% in the third quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock valued at $72,321,000 after buying an additional 27,205 shares during the last quarter. Asio Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $3,422,000. Finally, Robeco Institutional Asset Management B.V. raised its position in Regeneron Pharmaceuticals by 116.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after buying an additional 140,966 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $654.27 on Friday. The stock has a market capitalization of $69.17 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 1.37 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 12 month low of $532.60 and a 12 month high of $821.11. The firm’s 50 day simple moving average is $654.32 and its 200-day simple moving average is $726.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the previous year, the firm earned $8.22 EPS. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Cantor Fitzgerald restated an “overweight” rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Finally, Piper Sandler cut their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.